Forge Biologics to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 14, 2022 12:00 UTC

COLUMBUS, Ohio--(BUSINESS WIRE)-- Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics, and David Dismuke, Ph.D., Chief Technical Officer, will be presenting at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit virtually on Monday, April 25, 2022, at 1:30 p.m. Eastern Time.

The company presentation will be delivered via live webcast and may be accessed for 90 days by visiting Forge’s Events website at

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit


Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications

Business Development
Magdalena Tyrpien
Senior Vice President, Head of Business Development

Client Development
John Maslowski
Chief Commercial Officer

Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations


Source: Forge Biologics

Back to news